Camrelizumab, previously known as SHR-1210, represents a significant advancement in tumor treatment, functioning as a monoclonal that targets the programmed cell death 1 receptor. This control protein, expressed on immune cells , normally suppresses anti-tumor immune responses, allowing tumor cells to evade detection by the body’s immune system .